 |
15 Diseases |  |
0 Trials |
|
0 Trials |  |
23 News |  |
- palucorcel (CNTO 2476) / J&J
Phase classification: PRELUDE: A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy (clinicaltrials.gov) - Feb 12, 2025
P2, N=21, Completed, Sponsor: Janssen Research & Development, LLC
Phase classification: P2b --> P2
- || palucorcel (CNTO 2476) / J&J
Clinical, P2b data, Journal: Safety and Efficacy of Subretinally Administered Palucorcel for Geographic Atrophy of Age-Related Macular Degeneration: Phase 2b Study. (Pubmed Central) - Feb 10, 2020
Phase classification: P2b --> P2 Palucorcel was delivered successfully to the targeted subretinal site using a novel delivery system and suprachoroidal approach for most participants; however, improvement in GA area, retardation of growth, or visual acuity were not demonstrated.
- | palucorcel (CNTO 2476) / J&J
Journal: Subretinal Human Umbilical Tissue-Derived Cell Transplantation Preserves Retinal Synaptic Connectivity and Attenuates Müller Glial Reactivity. (Pubmed Central) - Jul 7, 2019
Human umbilical tissue-derived cells (hUTC or palucorcel) are currently under clinical investigation for the treatment of geographic atrophy, a late stage of macular degeneration, but how hUTC transplantation mediates vision recovery is not fully elucidated...hUTC transplantation strongly attenuates the reactivity of Müller glia in RCS rats. These findings highlight novel cellular and molecular mechanisms within the neural retina which underlie disease mechanisms and pinpoint Müller glia as a novel cellular target for hUTC transplantation.
- | palucorcel (CNTO 2476) / J&J
Trial completion: PRELUDE: A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy (clinicaltrials.gov) - Jul 5, 2019
P2b, N=21, Completed, Sponsor: Janssen Research & Development, LLC
These findings highlight novel cellular and molecular mechanisms within the neural retina which underlie disease mechanisms and pinpoint Müller glia as a novel cellular target for hUTC transplantation. Active, not recruiting --> Completed
- | palucorcel (CNTO 2476) / J&J
Trial primary completion date: PRELUDE: A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy (clinicaltrials.gov) - Aug 27, 2018
P2b, N=21, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Trial primary completion date: Dec 2018 --> May 2019
- | palucorcel (CNTO 2476) / J&J
Enrollment closed, Enrollment change: PRELUDE: A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy (clinicaltrials.gov) - Jan 17, 2018
P2b, N=21, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Dec 2018 --> May 2019 N=285 --> 21 | Recruiting --> Active, not recruiting
- palucorcel (CNTO 2476) / J&J
Enrollment change, Trial withdrawal: Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) (clinicaltrials.gov) - Dec 22, 2017
P2, N=0, Withdrawn, Sponsor: Janssen Pharmaceutical K.K.
N=285 --> 21 | Recruiting --> Active, not recruiting N=60 --> 0 | Not yet recruiting --> Withdrawn
- | palucorcel (CNTO 2476) / J&J
Phase classification: Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) (clinicaltrials.gov) - Sep 19, 2017
P2, N=60, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.
N=60 --> 0 | Not yet recruiting --> Withdrawn Phase classification: P=N/A --> P2
- | palucorcel (CNTO 2476) / J&J
Trial completion: A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration (clinicaltrials.gov) - Aug 8, 2017
P1/2, N=39, Completed, Sponsor: Janssen Research & Development, LLC
Phase classification: P=N/A --> P2 Active, not recruiting --> Completed
- | palucorcel (CNTO 2476) / J&J
Phase classification: Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) (clinicaltrials.gov) - May 9, 2017
P=N/A, N=0, Withheld, Sponsor: [Redacted]
Active, not recruiting --> Completed Phase classification: P2 --> P=N/A
- ||| palucorcel (CNTO 2476) / J&J
Trial initiation date: Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) (clinicaltrials.gov) - Feb 23, 2017
P2, N=60, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.
Phase classification: P2 --> P=N/A Initiation date: Mar 2017 --> Apr 2018
- ||| palucorcel (CNTO 2476) / J&J
Trial initiation date: Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) (clinicaltrials.gov) - Oct 31, 2016
P2, N=60, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.
Initiation date: Mar 2017 --> Apr 2018 Initiation date: Oct 2016 --> Mar 2017
- || palucorcel (CNTO 2476) / J&J
Trial primary completion date: PRELUDE: A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy (clinicaltrials.gov) - Oct 26, 2016
P2b, N=285, Recruiting, Sponsor: Janssen Research & Development, LLC
Initiation date: Oct 2016 --> Mar 2017 Trial primary completion date: Dec 2017 --> Dec 2018
- | palucorcel (CNTO 2476) / J&J
Enrollment change: A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration (clinicaltrials.gov) - Oct 11, 2016
P1/2, N=39, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Dec 2017 --> Dec 2018 N=24 --> 39
- ||||| palucorcel (CNTO 2476) / J&J
New P2 trial: Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) (clinicaltrials.gov) - Sep 12, 2016
P2, N=60, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.
- | palucorcel (CNTO 2476) / J&J
Phase classification: PRELUDE: A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy (clinicaltrials.gov) - Aug 25, 2016
P2b, N=255, Recruiting, Sponsor: Janssen Research & Development, LLC
N=24 --> 39 Phase classification: P2 --> P2b
- |||| palucorcel (CNTO 2476) / J&J
Enrollment open: PRELUDE: A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy (clinicaltrials.gov) - Apr 4, 2016
P2, N=255, Recruiting, Sponsor: Janssen Research & Development, LLC
Phase classification: P2 --> P2b Not yet recruiting --> Recruiting
- ||||| palucorcel (CNTO 2476) / J&J
New P2 trial: PRELUDE: A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy (clinicaltrials.gov) - Jan 20, 2016
P2, N=255, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | palucorcel (CNTO 2476) / J&J
Enrollment closed, Enrollment change: A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration (clinicaltrials.gov) - Oct 23, 2014
P1/2, N=24, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Suspended --> Active, not recruiting | N=68 --> 24
- | palucorcel (CNTO 2476) / J&J
Trial suspension: A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration (clinicaltrials.gov) - Jan 21, 2014
P1/2, N=68, Suspended, Sponsor: Janssen Research & Development, LLC
Suspended --> Active, not recruiting | N=68 --> 24 Recruiting --> Suspended
- | palucorcel (CNTO 2476) / J&J
Enrollment change: A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration (clinicaltrials.gov) - Oct 24, 2012
P1/2, N=68, Suspended, Sponsor: Janssen Research & Development, LLC
Recruiting --> Suspended N=56 --> 68